Skip to main content
Figure 4 | Orphanet Journal of Rare Diseases

Figure 4

From: Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule

Figure 4

Effect of naked -DNA treatment on the course of disease in ALS transgenic SOD1G93A mice. A. Table of the onset of symptoms and mortality of SOD1G93A transgenic mice treated with naked DNA TTC, BDNF-TTC, BDNF and empty-plasmid (positive control) (n = 10 mice per group, balanced males and females). B. Cumulative probability of the onset of disease symptoms (hanging-wire test) and survival (D) in SOD1G93A mice injected at 60 days of age with TTC, BDNF-TTC, BDNF or empty (positive control) plasmids. Bar graphs representing the average age of disease onset (C) and life span (E). F. Weight measurements of transgenic mice treated with the different constructions. G Strength and motor function were tested using the rotarod at 15 rpm. Mice were given up to 180 s for the test performance and the time at which mice fell was recorded (*, #, +, P < 0.05; **, ##, P < 0.01; error bars indicate SEM); * for BDNF-TTC vs. positive control comparisons; # for TTC vs. control comparisons; + for BDNF vs. positive control comparisons.

Back to article page